|
CA3041279A1
(en)
|
2016-11-28 |
2018-05-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding domain, and polypeptide including conveying section
|
|
AU2017364818C1
(en)
|
2016-11-28 |
2025-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand binding activity
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
IL321812A
(en)
|
2017-08-03 |
2025-08-01 |
Synthorx Inc |
Cytokine complexes for the treatment of autoimmune diseases
|
|
CN118126157A
(zh)
|
2017-08-03 |
2024-06-04 |
美国安进公司 |
白介素-21突变蛋白和治疗方法
|
|
KR20200089312A
(ko)
|
2017-11-28 |
2020-07-24 |
추가이 세이야쿠 가부시키가이샤 |
리간드 결합 활성을 조정 가능한 리간드 결합 분자
|
|
KR20250134208A
(ko)
|
2017-11-28 |
2025-09-09 |
추가이 세이야쿠 가부시키가이샤 |
항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
MX2020007291A
(es)
|
2018-01-12 |
2020-09-10 |
Amgen Inc |
Anticuerpos anti-pd-1 y metodos de tratamiento.
|
|
US20210130430A1
(en)
|
2018-05-14 |
2021-05-06 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
MX2020012251A
(es)
|
2018-05-14 |
2021-04-28 |
Werewolf Therapeutics Inc |
Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
|
|
EP3824096A4
(en)
*
|
2018-07-18 |
2022-04-20 |
AskGene Pharma Inc. |
NOVEL ANTIBODIES AND METHODS FOR THE PRODUCTION AND USE THEREOF
|
|
WO2020023702A1
(en)
|
2018-07-25 |
2020-01-30 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
CA3098930A1
(en)
|
2018-09-21 |
2020-03-26 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel interleukin-2 and use thereof
|
|
CN112105634B
(zh)
|
2018-09-21 |
2024-03-12 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
|
CN113286812B
(zh)
|
2018-09-27 |
2025-05-30 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
MA54952A
(fr)
|
2019-02-06 |
2022-05-11 |
Synthorx Inc |
Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
|
|
EP3930687A4
(en)
|
2019-02-25 |
2023-06-07 |
The University of Chicago |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
|
|
BR112021022666A2
(pt)
|
2019-05-14 |
2022-03-29 |
Werewolf Therapeutics Inc |
Frações de separação e seus métodos e uso
|
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
AU2020285636A1
(en)
*
|
2019-05-24 |
2021-11-04 |
Proviva Therapeutics (Hong Kong) Limited |
IL-2 compositions and methods of use thereof
|
|
EP3981428A4
(en)
|
2019-06-05 |
2023-07-12 |
Chugai Seiyaku Kabushiki Kaisha |
Protease substrate, and polypeptide including protease cleavage sequence
|
|
CN114341189A
(zh)
|
2019-06-12 |
2022-04-12 |
奥美药业有限公司 |
全新il-15前药及其应用
|
|
EP4004026A4
(en)
*
|
2019-07-25 |
2023-11-15 |
Trutino Biosciences Inc. |
IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER
|
|
WO2021024020A1
(en)
*
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
EP4013775A1
(en)
*
|
2019-08-12 |
2022-06-22 |
Askgene Pharma, Inc. |
Il-2 fusion proteins that preferentially bind il-2ralpha
|
|
WO2021050554A1
(en)
|
2019-09-10 |
2021-03-18 |
Synthorx, Inc. |
Il-2 conjugates and methods of use to treat autoimmune diseases
|
|
WO2021062406A1
(en)
*
|
2019-09-28 |
2021-04-01 |
AskGene Pharma, Inc. |
Cytokine prodrugs and dual-prodrugs
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
AU2020403148A1
(en)
*
|
2019-12-13 |
2022-06-30 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
IL293978A
(en)
*
|
2019-12-20 |
2022-08-01 |
Regeneron Pharma |
New il2 agonists and methods of using them
|
|
CA3162320A1
(en)
|
2019-12-23 |
2021-07-01 |
Alexander V. SHIROKOV |
Methods of preparing n6-((2-azidoethoxy)carbonyl)lysine
|
|
KR20220140514A
(ko)
|
2020-01-10 |
2022-10-18 |
브라이트 피크 테라퓨틱스 아게 |
변형된 il-2 폴리펩타이드 및 그의 용도
|
|
AU2021205981A1
(en)
*
|
2020-01-11 |
2022-07-14 |
AskGene Pharma, Inc. |
Novel masked cytokines and methods of use thereof
|
|
US20240043489A1
(en)
*
|
2020-01-15 |
2024-02-08 |
Trutino Biosciences Inc. |
Cytokine Prodrugs Comprising a Cleavable Linker
|
|
CN115943210A
(zh)
|
2020-01-20 |
2023-04-07 |
中外制药株式会社 |
配体结合融合蛋白
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
MX2022011676A
(es)
*
|
2020-03-23 |
2023-03-08 |
Zymeworks Bc Inc |
Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
|
|
BR112022019708A2
(pt)
*
|
2020-04-01 |
2022-12-20 |
Xilio Dev Inc |
Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
|
|
PH12022552627A1
(en)
*
|
2020-04-01 |
2023-01-04 |
Xilio Dev Inc |
Masked il-2 cytokines and their cleavage products
|
|
PH12022552630A1
(en)
*
|
2020-04-01 |
2023-01-04 |
Xilio Dev Inc |
Masked il-15 cytokines and their cleavage products
|
|
AU2021254283B2
(en)
|
2020-04-10 |
2025-12-11 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
CN115996946A
(zh)
*
|
2020-04-30 |
2023-04-21 |
免疫靶向有限公司 |
可活化il2组合物和使用方法
|
|
KR20230010251A
(ko)
|
2020-05-13 |
2023-01-18 |
보넘 테라퓨틱스, 인크. |
단백질 복합체의 조성물 및 그의 사용 방법
|
|
MX2023000734A
(es)
*
|
2020-07-14 |
2023-02-13 |
Pfizer |
Virus vaccinia recombinante.
|
|
CN116323653A
(zh)
*
|
2020-09-04 |
2023-06-23 |
山东先声生物制药有限公司 |
Il-2突变体及其应用
|
|
KR20230104866A
(ko)
*
|
2020-09-16 |
2023-07-11 |
베이진 엘티디 |
인터류킨 15 작제물 및 사용 방법
|
|
EP4215542A4
(en)
*
|
2020-09-18 |
2024-11-20 |
Miyagi Prefectural Hospital Organization |
MUTANT IL-2 PROTEIN AND DRUG CONTAINING IT
|
|
TWI815194B
(zh)
*
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
EP4251187A4
(en)
*
|
2020-11-25 |
2025-09-10 |
Xilio Dev Inc |
TUMOR-SPECIFIC CLASSIBLE LINKERS
|
|
EP4284819A1
(en)
*
|
2021-02-01 |
2023-12-06 |
Askgene Pharma, Inc. |
Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide
|
|
CN112553256B
(zh)
*
|
2021-02-20 |
2021-06-22 |
北京百普赛斯生物科技股份有限公司 |
Il-2受体复合物及其制备方法与应用
|
|
KR20230157448A
(ko)
|
2021-03-16 |
2023-11-16 |
싸이톰스 테라퓨틱스, 인크. |
마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
|
|
AU2022261268A1
(en)
*
|
2021-04-22 |
2023-11-16 |
Guangdong Fapon Biopharma Inc. |
Bispecific multifunctional fusion polypeptide
|
|
TW202317623A
(zh)
|
2021-06-14 |
2023-05-01 |
美商再生元醫藥公司 |
基於il2之治療劑及其使用方法
|
|
WO2022262496A1
(en)
*
|
2021-06-17 |
2022-12-22 |
Suzhou Fuse Biosciences Limited |
Immunoconjugate molecules and related methods and compositions thereof
|
|
KR20240034221A
(ko)
|
2021-07-09 |
2024-03-13 |
브라이트 피크 테라퓨틱스 아게 |
염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
|
|
WO2023281482A1
(en)
*
|
2021-07-09 |
2023-01-12 |
Bright Peak Therapeutics Ag |
Cd20-targeted il-2 and its uses
|
|
AU2022306788A1
(en)
*
|
2021-07-09 |
2024-01-04 |
Bright Peak Therapeutics Ag |
Conjugates of checkpoint inhibitors with il-2, and uses thereof
|
|
MX2024000867A
(es)
*
|
2021-07-21 |
2024-03-14 |
Trutino Biosciences Inc |
Polipeptidos enlazadores.
|
|
WO2023004004A1
(en)
*
|
2021-07-23 |
2023-01-26 |
Merck Sharp & Dohme Llc |
Il-2 muteins for treating cancer or infection
|
|
JP2024538042A
(ja)
*
|
2021-10-13 |
2024-10-18 |
シートムエックス セラピューティクス，インコーポレイテッド |
三量体活性化可能サイトカイン構成体ならびに関連する組成物及び方法
|
|
WO2023131270A1
(en)
*
|
2022-01-07 |
2023-07-13 |
Cure Genetics, Co., Limited |
Novel interleukin-2 polypeptides
|
|
EP4473007A1
(en)
*
|
2022-01-31 |
2024-12-11 |
Aarhus Universitet |
A biopharmaceutical prodrug platform based on protein conformational change
|
|
EP4477673A4
(en)
*
|
2022-02-11 |
2025-09-03 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
IMMUNOCONJUGATE AND ITS USE
|
|
WO2023161853A1
(en)
*
|
2022-02-23 |
2023-08-31 |
Bright Peak Therapeutics Ag |
Activatable il-18 polypeptides
|
|
CA3245295A1
(en)
*
|
2022-03-03 |
2025-06-13 |
Hainan Simcere Pharmaceutical Co., Ltd. |
Pharmaceutical Composition of Il2 Antibody-Mutant FC Block Fusion Protein and its Use
|
|
CN114853909A
(zh)
*
|
2022-05-13 |
2022-08-05 |
南京吉盛澳玛生物医药有限公司 |
新型IL-2与INFα和Fc融合蛋白的设计、制备及用途
|
|
WO2023222886A1
(en)
*
|
2022-05-20 |
2023-11-23 |
Depth Charge Ltd |
Antibody-cytokine fusion proteins
|
|
EP4580755A1
(en)
*
|
2022-09-02 |
2025-07-09 |
Novimmune S.A. |
Reciprocally masked antibody-cytokine fusion proteins and methods of use thereof
|
|
CN117917438A
(zh)
*
|
2022-10-21 |
2024-04-23 |
北京诺诚健华医药科技有限公司 |
抗体融合蛋白及其制备和应用
|
|
WO2024119193A2
(en)
*
|
2022-12-02 |
2024-06-06 |
AskGene Pharma, Inc. |
Mutant il-2 polypeptides and il-2 prodrugs
|
|
WO2024150175A1
(en)
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated proteins and methods of use
|
|
WO2024150174A1
(en)
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated immunocytokines and methods of use
|
|
GB202301945D0
(en)
|
2023-02-10 |
2023-03-29 |
Mount Natalie |
Novel immunoconjugates
|
|
EP4450093A1
(en)
|
2023-04-17 |
2024-10-23 |
Synaffix B.V. |
Cleavable immune cell engagers
|
|
WO2024218162A1
(en)
|
2023-04-17 |
2024-10-24 |
Synaffix B.V. |
Cleavable immune cell engagers
|
|
JP2026521042A
(ja)
*
|
2023-06-22 |
2026-06-25 |
オーフス ユニバーシテット |
多重特異的タンパク質性プロドラッグ構築物
|
|
EP4750799A1
(en)
*
|
2023-07-27 |
2026-06-03 |
Binacea Pharma, Inc. |
Mutant il-2 fusions with immune cell specific binding proteins and methods of use thereof
|
|
WO2025041101A1
(en)
|
2023-08-23 |
2025-02-27 |
Bright Peak Therapeutics Ag |
Activatable il-18 immunocytokines and uses thereof
|
|
WO2025122660A1
(en)
*
|
2023-12-04 |
2025-06-12 |
AskGene Pharma, Inc. |
Chimeric proteins comprising masked il-2
|
|
WO2025122614A1
(en)
*
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
WO2025151752A1
(en)
|
2024-01-10 |
2025-07-17 |
Xilio Development, Inc. |
Masked il-2 cytokines and methods of use thereof
|
|
WO2025162454A1
(zh)
*
|
2024-02-02 |
2025-08-07 |
北京昌平实验室 |
双特异性抗体和细胞因子融合蛋白及其应用
|
|
WO2025165594A1
(en)
*
|
2024-02-02 |
2025-08-07 |
Staidson Biopharma Inc. |
Anti-pd-l1 and il-15 prodrug bifunctional protein and uses thereof
|
|
WO2025201242A1
(en)
*
|
2024-03-25 |
2025-10-02 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof
|
|
WO2026083296A1
(en)
|
2024-10-16 |
2026-04-23 |
Bright Peak Therapeutics Ag |
Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
|
|
WO2026083295A1
(en)
|
2024-10-16 |
2026-04-23 |
Bright Peak Therapeutics Ag |
Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
|
|
WO2026099401A1
(en)
|
2024-11-07 |
2026-05-15 |
Cytospire Therapeutics Ltd |
Novel immunoconjugates
|
|
CN119639683A
(zh)
*
|
2024-12-21 |
2025-03-18 |
浙江大学绍兴研究院 |
一种表达il-15靶向b7h3的嵌合抗原受体-t细胞及其应用
|